PureTech Health plc (PRTC) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.13
↓-90% vs avg
5yr avg: 1.30
30Y Low0.1·High2.4
ROE
↓
-30.8%
↑-207% vs avg
5yr avg: -10.0%
30Y Low-66%·High103%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PRTC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
PureTech Health plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $41M | $40M | $498M | $779M | $908M | $1.1B | $1.6B | — | — | — | — |
| Enterprise Value | $-193352106 | $-194242959 | $240M | $613M | $805M | $647M | $1.3B | — | — | — | — |
| P/E Ratio → | -0.37 | — | 9.23 | — | — | — | 270.00 | — | — | — | — |
| P/S Ratio | 8.79 | 8.60 | 103.10 | 233.82 | 434.63 | 106.26 | 189.60 | — | — | — | — |
| P/B Ratio | 0.13 | 0.13 | 1.22 | 1.70 | 1.66 | 1.82 | 2.42 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PRTC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -41.69 | 49.61 | 184.05 | 385.35 | 64.81 | 150.36 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 7.08 | — | — | 33.23 | 22.38 | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
PRTC Profitability
Margins and return-on-capital ratios measuring operating efficiency
PureTech Health plc earns an operating margin of -2114.7%. Operating margins have expanded from -4390.4% to -2114.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -30.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 26.0% | -48.1% | -6546.2% | -1007.0% | 100.0% | -888.1% | -372.8% | -10828.5% | 64.6% |
| Operating Margin | -2114.7% | -2114.7% | -2818.9% | -4390.4% | -9464.4% | -1506.0% | -1433.1% | -1558.5% | -635.4% | -17756.9% | -1668.4% |
| Net Profit Margin | -2355.4% | -2355.4% | 1108.3% | -1972.9% | -2409.3% | -606.9% | 71.8% | 4847.4% | -266.7% | 4749.1% | -1101.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.8% | -30.8% | 12.4% | -13.1% | -8.9% | -9.8% | 0.9% | 103.0% | -37.8% | 39.5% | -38.0% |
| ROA | -19.3% | -19.3% | 8.3% | -9.4% | -6.1% | -6.3% | 0.6% | 60.9% | -11.2% | 9.7% | -15.6% |
| ROIC | -66.9% | -66.9% | -46.2% | -29.8% | -48.2% | -45.3% | -20.3% | -32.8% | -255.4% | -491.7% | -156.9% |
| ROCE | -18.8% | -18.8% | -22.6% | -23.4% | -29.8% | -19.7% | -14.8% | -27.7% | -86.0% | -143.7% | -56.7% |
PRTC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $254M exceeds total debt of $20M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.05 | 0.06 | 0.09 | 0.09 | 0.12 | 0.06 | 0.07 | 0.12 | 0.08 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.77 | -0.63 | -0.36 | -0.19 | -0.71 | -0.50 | -0.14 | -0.63 | -1.02 | -0.61 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.42 | -1.42 | 3.37 | -1.23 | -50.04 | 4.13 | 19.02 | 117.29 | -4.60 | -6.85 | -11.22 |
Net cash position: cash ($254M) exceeds total debt ($20M)
PRTC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
PureTech Health plc's current ratio of 6.59x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.76x to 6.59x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.59 | 6.59 | 9.33 | 6.76 | 3.99 | 2.22 | 2.29 | 1.21 | 0.98 | 0.72 | 1.41 |
| Quick Ratio | 6.59 | 6.59 | 9.33 | 6.76 | 3.99 | 2.10 | 2.29 | 1.21 | 0.98 | 0.73 | 1.42 |
| Cash Ratio | 6.02 | 6.02 | 8.87 | 6.37 | 3.61 | 2.06 | 2.23 | 1.17 | 0.94 | 0.69 | 1.38 |
| Asset Turnover | — | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.04 | 0.00 | 0.01 |
| Inventory Turnover | — | — | — | — | — | 3.95 | — | — | — | — | — |
| Days Sales Outstanding | — | 636.93 | 975.48 | 260.43 | 3904.45 | 131.27 | 128.61 | 97.76 | 29.61 | 1009.08 | 10.30 |
PRTC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
PureTech Health plc returns 5.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | 0.0% | — | 0.3% | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 10.8% | — | — | — | 0.4% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 5.0% | 5.1% | 21.6% | 2.5% | 2.9% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 5.0% | 5.1% | 21.6% | 2.5% | 2.9% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $2M | $27M | $28M | $28M | $29M | $29M | $29M | $27M | $24M | $23M |
Peer Comparison
Compare PRTC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PRTCYou | $41M | -0.4 | — | — | 100.0% | -2114.7% | -30.8% | -66.9% | — |
 ROIV | $21B | -117.8 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
 ATAI | $964M | -4.3 | — | — | 100.0% | -33341.2% | -82.7% | -45.0% | — |
 CMPS | $902M | -3.0 | — | — | — | — | -565.3% | — | — |
 RXRX | $1B | -2.3 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — |
 ABSI | $894M | -6.8 | — | — | -319.4% | -4454.2% | -62.5% | -58.0% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRTA | $567M | -2.3 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ALDX | $104M | -1.8 | — | — | — | — | -58.5% | -369.4% | — |
 JNJ | $536B | 38.4 | 18.6 | 27.0 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See PRTC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRTC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRTC vs ROIV
Side-by-side business, growth, and profitability comparison vs Roivant Sciences Ltd..
Start ComparisonPRTC — Frequently Asked Questions
Quick answers to the most common questions about buying PRTC stock.
What is PureTech Health plc's P/E ratio?
PureTech Health plc's current P/E ratio is -0.4x. The historical average is 9.2x.
What is PureTech Health plc's ROE?
PureTech Health plc's return on equity (ROE) is -30.8%. The historical average is -6.3%.
Is PRTC stock overvalued?
Based on historical data, PureTech Health plc is trading at a P/E of -0.4x. Compare with industry peers and growth rates for a complete picture.
What are PureTech Health plc's profit margins?
PureTech Health plc has 100.0% gross margin and -2114.7% operating margin.